Monday, March 24, 2025 6:14:59 PM
How do we determine/value a fair stock price for ELTP?
1. Methotrexate launched on 8/27/24 ~$63 Million market https://elite.irpass.com/Elite-Pharmaceuticals-Announces-Commercial-Launch-of-Generic-Methotrexate-Sodium-8-27-2024
2. Codeine with acetaminophen launched on 10/7/24 ~$47 Million market https://elite.irpass.com/Elite-Pharmaceuticals-Announces-Commercial-Launch-of-Acetaminophen-and-Codeine-Phosphate-Tablets-10-7-2024
3. Hydrocodone with acetaminophen launched on 12/2/24 ~$300 Million market https://elite.irpass.com/irpass.asp?ResLibraryID=140659&BzID=2258&L=1&s=0&G=939&Nav=0
4. Generic Vyvanse launched on 12/26/24 ~$4.3 Billion martket https://elite.irpass.com/irpass.asp?ResLibraryID=141273&BzID=2258&L=1&s=0&G=939&Nav=0
5.Elite Pharmaceuticals, Inc. Announces First Shipment Of Product From New Facility And Packaging Line
https://elite.irpass.com/Elite-Pharmaceuticals--Inc--Announces-First-Shipment-of-Product-from-New-Facility-and-Packaging-Line-3-3-2025
6.Abuse Deterrent Technology
Many catalysts are on deck to fuel ELTP to rocket up again.
1. Launch of generic Percocet in less than 7 days.~$500 million market
2. Launch of generic Dolophine (methadone) ~before or on 5/30/25 ~$30 million market
3. Pending acquisition and merger news
4. Pending generic Adderall IR launch in Israel
5. Pending positive ruling for Elite with generic OxyContin
6. Record breaking quarterly revenue report on 6/30/25
7. April 1 - Elite terminates Prasco Agreement and begins marketing Adderall XR 100% by themselves
8. April 2- Tariffs begin - wild card for merger/acquisition premium
https://thehill.com/policy/healthcare/5164970-eli-lilly-27-billion-new-domestic-plants/amp/
https://www.reuters.com/business/jj-plans-invest-more-than-55-billion-us-over-next-four-years-2025-03-21/
9. Pending Dopamine Agonist approval
10. Pending India R&D Agreement signed
11. Pending Positive BE studies (Concerta and Undisclosed)
https://fullratio.com/pe-ratio-by-industry
Share Price = EPS x P/E Ratio$0.2172 = $.01 x 21.72$0.4344 = $.02 x 21.72$0.6516 = $.03 x 21.72$0.8688 = $.04 x 21.72$1.0860 = $.05 x 21.72$1.3032 = $.06 x 21.72$1.5204 = $.07 x 21.72$1.7376 = $.08 x 21.72$1.9548 = $.09 x 21.72$2.1720 = $.10 x 21.72
1. Methotrexate launched on 8/27/24 ~$63 Million market https://elite.irpass.com/Elite-Pharmaceuticals-Announces-Commercial-Launch-of-Generic-Methotrexate-Sodium-8-27-2024
2. Codeine with acetaminophen launched on 10/7/24 ~$47 Million market https://elite.irpass.com/Elite-Pharmaceuticals-Announces-Commercial-Launch-of-Acetaminophen-and-Codeine-Phosphate-Tablets-10-7-2024
3. Hydrocodone with acetaminophen launched on 12/2/24 ~$300 Million market https://elite.irpass.com/irpass.asp?ResLibraryID=140659&BzID=2258&L=1&s=0&G=939&Nav=0
4. Generic Vyvanse launched on 12/26/24 ~$4.3 Billion martket https://elite.irpass.com/irpass.asp?ResLibraryID=141273&BzID=2258&L=1&s=0&G=939&Nav=0
5.Elite Pharmaceuticals, Inc. Announces First Shipment Of Product From New Facility And Packaging Line
https://elite.irpass.com/Elite-Pharmaceuticals--Inc--Announces-First-Shipment-of-Product-from-New-Facility-and-Packaging-Line-3-3-2025
6.Abuse Deterrent Technology
Many catalysts are on deck to fuel ELTP to rocket up again.
1. Launch of generic Percocet in less than 7 days.~$500 million market
2. Launch of generic Dolophine (methadone) ~before or on 5/30/25 ~$30 million market
3. Pending acquisition and merger news
4. Pending generic Adderall IR launch in Israel
5. Pending positive ruling for Elite with generic OxyContin
6. Record breaking quarterly revenue report on 6/30/25
7. April 1 - Elite terminates Prasco Agreement and begins marketing Adderall XR 100% by themselves
8. April 2- Tariffs begin - wild card for merger/acquisition premium
https://thehill.com/policy/healthcare/5164970-eli-lilly-27-billion-new-domestic-plants/amp/
https://www.reuters.com/business/jj-plans-invest-more-than-55-billion-us-over-next-four-years-2025-03-21/
9. Pending Dopamine Agonist approval
10. Pending India R&D Agreement signed
11. Pending Positive BE studies (Concerta and Undisclosed)
https://fullratio.com/pe-ratio-by-industry
Share Price = EPS x P/E Ratio$0.2172 = $.01 x 21.72$0.4344 = $.02 x 21.72$0.6516 = $.03 x 21.72$0.8688 = $.04 x 21.72$1.0860 = $.05 x 21.72$1.3032 = $.06 x 21.72$1.5204 = $.07 x 21.72$1.7376 = $.08 x 21.72$1.9548 = $.09 x 21.72$2.1720 = $.10 x 21.72
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
